Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Sep 26, 2020 11:27am
523 Views
Post# 31625268

RE:RE:If you look at the last two years, the share price

RE:RE:If you look at the last two years, the share priceFor me, entering sub .10 5 years ago, have seen sp expand to new highs and regress to new lows, to say the least its been a roller coaster ride. IMHO, at this sp and stage of development it will be a rocket ride northward at varying degrees of lift. I truly believe , what all investors know at this stage heading into phase 2b/3 presents a solid cases for the Best in Class NSAID, with superior GI safe results, superior womac scores, and no BP increases, and comparing to other NSAID's nothing any worse. With Dr. Stauffer, with past work at FDA, at the helm developing the approach for final FDA approval provides a comfort that all particulars are being developed NOT to fail. Although the SP is what it is, upcoming happenings will lift the SP to the target SP and from there to the NAZ. For anyone wishing for 5X plus bagger in next 2 years  ATEis an exceptional low risk place to be. Insider open market purchasing is surely an idication od their commitment and faith in success!.............................
Danorrn wrote: Then and only then* rather THAN "than". However, it previous excursions down it usually rides up to around .70 first. If I'm remembering correctly.


Bullboard Posts